Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of β-Cells
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Immune modulators can arrest loss of insulin secretion in type 1 diabetes mellitus (T1DM), but they have not caused permanent disease remission or restored normal insulin secretion. We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of β-cells. Diabetic NOD mice treated with anti-CD3 mAb and exendin-4 had a higher rate of remission (44%) than mice treated with anti-CD3 mAb alone (37%) or exendin-4 (0%) or insulin or IgG alone (0%) (P < 0.01). The effect of exendin-4 on reversal of diabetes after anti-CD3 mAb was greatest in mice with a glucose level of less than 350 mg/dl at diagnosis (63 vs. 39%, P < 0.05). Exendin-4 did not affect β-cell area, replication, or apoptosis or reduce the frequency of diabetogenic or regulatory T cells or modulate the antigenicity of islet cells. Reversal of T1DM with anti-CD3 mAb was associated with recovery of insulin in glucose transporter-2+/insulin− islet cells that were identified at diagnosis. Glucose tolerance and insulin responses improved in mice treated with combination therapy, and exendin-4 increased insulin content and insulin release from β-cells. We conclude that treatment with glucagon-like peptide-1 receptor agonist enhances remission of T1DM in NOD mice treated with anti-CD3 mAb by enhancing the recovery of the residual islets. This combinatorial approach may be useful in treatment of patients with new-onset T1DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [20]
Citations
Cites
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099 · cited 2×
“In the European study, the clinical response to drug treatment was most apparent in those subjects in whom the magnitude of the Cpeptide response to a glucose clamp at diagnosis was in the upper half of C-peptide responses of all subjects at diagnosis (3).”
BackgroundAnti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
Chatenoud, L., Thervet, E., Primo, J., & Bach, J. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.123 · Cited by 664 · cited 2×
“(32) and recently reported by our group (18, 31).”
BackgroundFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 634
Self-citationGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Belghith, M., Bluestone, J. A., Barriot, S., Mégret, J., Bach, J.-F., & Chatenoud, L. (2003) · Nature Medicine · doi:10.1038/nm924 · Cited by 586
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576 · cited 2×
“075 g ip for 10 d, beginning at the onset of hyperglycemia (9, 10, 19).”
Background
Cited by
Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
Hu, C.-Y., Rodriguez-Pinto, D., Du, W., Ahuja, A., Henegariu, O., Wong, F. S., Shlomchik, M. J., & Wen, L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32405 · Cited by 426
Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice
Tschen, S.-I., Dhawan, S., Gurlo, T., & Bhushan, A. (2009) · Diabetes · doi:10.2337/db08-1651 · Cited by 331
Keymeulen, B., Walter, M., Mathieu, C., Kaufman, L., Gorus, F., Hilbrands, R., Vandemeulebroucke, E., Van de Velde, U., Crenier, L., De Block, C., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1644-9 · Cited by 317
“Since the beta cell mass is already markedly reduced at clinical onset of type 1 diabetes [18, 19], it is likely that any immune-modulating intervention will have to be associated with, or followed by, a beta cell replacement therapy, as recently tested in rodents [20]; a combination with other methods for tolerance-i…”
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“[78] Sherry NA, Chen W, Kushner JA, et al.”
BackgroundType 1 diabetes as a relapsing–remitting disease?
von Herrath, M., Sanda, S., & Herold, K. (2007) · Nature Reviews Immunology · doi:10.1038/nri2192 · Cited by 270
Self-citationRigby, M. R., DiMeglio, L. A., Rendell, M. S., Felner, E. I., Dostou, J. M., Gitelman, S. E., Patel, C. M., Griffin, K. J., Tsalikian, E., Gottlieb, P. A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70111-6 · Cited by 209
Self-citationTherapeutic Anti-Cd3 Monoclonal Antibodies: From Bench to Bedside
Kuhn, C., & Weiner, H. L. (2016) · Immunotherapy · doi:10.2217/imt-2016-0049 · Cited by 195
Suarez-Pinzon, W. L., Power, R. F., Yan, Y., Wasserfall, C., Atkinson, M., & Rabinovitch, A. (2008) · Diabetes · doi:10.2337/db08-0688 · Cited by 187
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166
“The regenerative and cytoprotective effects of glucagon-like peptide-1 (GLP-1) on beta cells have engendered considerable interest in whether GLP-1 may be useful for the treatment of type 1 diabetes, either in combination with immunomodulation [3–6] or as adjunctive therapy in islet transplantation [7–10].”
Backgroundβ-Cell Mass and Type 1 Diabetes
Akirav, E., Kushner, J. A., & Herold, K. C. (2008) · Diabetes · doi:10.2337/db07-1817 · Cited by 146
Self-citationCurrent and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 173
Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
Luo, X., Herold, K. C., & Miller, S. D. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.002 · Cited by 136
“For example, the combination of a glucagon-like peptide 1 (GLP-1) receptor agonist (Exendin-4) was found to augment b cell function in diabetic mice treated with anti-CD3 mAb or ATG (Ogawa et al., 2004; Sherry et al., 2007).”
BackgroundSelf-citationChen, Y.-G., Mathews, C. E., & Driver, J. P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00051 · Cited by 134
“Preclinical studies using these modalities demonstrated an ability to reverse T1D in 39% of NOD females after onset (25).”
Rother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Tian, L., Gao, J., Hao, J., Zhang, Y., Yi, H., O'Brien, T. D., Sorenson, R., Luo, J., & Guo, Z. (2010) · Endocrinology · doi:10.1210/en.2010-0068 · Cited by 120
“A significant increase of replicating -cells also was not found in NOD mice treated with anti-CD3 monoclonal antibodies and exendin-4, when Ki67 was used as a marker (40).”
MethodMatthews, J. B., Staeva, T. P., Bernstein, P. L., Peakman, M., & Von Herrath, M. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04153.x · Cited by 114
Type 1 Diabetes: Current Concepts in Epidemiology, Pathophysiology, Clinical Care, and Research
Gan, M. J., Albanese-O’Neill, A., & Haller, M. J. (2012) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2012.07.002 · Cited by 159
Exendin-4 modulates diabetes onset in nonobese diabetic mice
Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2007-1137 · Cited by 110
Phillips, J. M., Parish, N. M., Bland, C., Sawyer, Y., De La Peña, H., & Cooke, A. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.97 · Cited by 110
“Recent studies have shown improved β-cell recovery in diabetic NOD mice when they are given anti-CD3 combined with exendin-4 [30].”
BackgroundStopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
Skyler, J. S., & Ricordi, C. (2011) · Diabetes · doi:10.2337/db10-1114 · Cited by 109
“This potential approach involves the use of a number of agents, including 1) an anti-inflammatory agent, such as an anti– interleukin-1 or an anti-tumor necrosis factor, since considerable evidence exists that pancreatic islets are engulfed by an inflammatory response in both type 1 and type 2 diabetes (29); 2) transi…”
BackgroundSynergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade
Ablamunits, V., Henegariu, O., Hansen, J. B., Opare-Addo, L., Preston-Hurlburt, P., Santamaria, P., Mandrup-Poulsen, T., & Herold, K. C. (2012) · Diabetes · doi:10.2337/db11-1033 · Cited by 107
Self-citationKim, S.-J., Nian, C., Doudet, D. J., & McIntosh, C. H. S. (2009) · Diabetes · doi:10.2337/db08-1101 · Cited by 106
“The long-acting GLP-1 receptor agonist exendin-4, has been shown to synergize with anti-CD3 monoclonal antibody treatment in reversing diabetes in NOD mice by enhancing the recovery of -cells (49).”
BackgroundImmune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies?
Chatenoud, L. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.275 · Cited by 114
Small-Molecule Inducer of β Cell Proliferation Identified by High-Throughput Screening
Shen, W., Tremblay, M. S., Deshmukh, V. A., Wang, W., Filippi, C. M., Harb, G., Zhang, Y.-Q., Kamireddy, A., Baaten, J., Jin, Q., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja309304m · Cited by 99
The Role of Dendritic Cells in Tissue-Specific Autoimmunity
Mbongue, J. C., Nicholas, D., Firek, A. F., & Langridge, W. H. R. (2014) · Journal of Immunology Research · doi:10.1155/2014/857143 · Cited by 103
Portha, B., Tourrel-Cuzin, C., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/376509 · Cited by 85
“Ex-4 has also been administered to NOD mice alone or in combination with different immune modulators, lisofylline [98], antilymphocyte serum [99], or anti-CD3 immunotherapy [100]: the highest frequency of diabetes remission was observed in animals that received the combination treatments, suggesting a beneficial syner…”
BackgroundThe Long and Winding Road to Understanding and Conquering Type 1 Diabetes
Santamaría, P. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.003 · Cited by 100
“However, whether immunotherapies capable of restoring normoglycemia do so by enabling b cell regeneration and/or replication or by promoting functional recovery of residual b cells is unclear (Ogawa et al., 2004; Phillips et al., 2007; Sherry et al., 2007).”
BackgroundBreakdown in Peripheral Tolerance in Type 1 Diabetes in Mice and Humans
Jeker, L. T., Bour-Jordan, H., & Bluestone, J. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007807 · Cited by 95
“The efficacy of both ATG and FNB anti-CD3 mAbs in new-onset diabetic NOD mice was enhanced in combination with exendin-4, a reagent that improved the functional recovery of residual islets (Ogawa et al. 2004; Sherry et al. 2007).”
BackgroundSelf-citationCombination immunotherapies for type 1 diabetes mellitus
Pozzilli, P., Maddaloni, E., & Buzzetti, R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.8 · Cited by 83
Parker, M. J., Xue, S., Alexander, J. J., Wasserfall, C. H., Campbell-Thompson, M. L., Battaglia, M., Gregori, S., Mathews, C. E., Song, S., Troutt, M., et al. (2009) · Diabetes · doi:10.2337/db09-0557 · Cited by 76
“Previous reports (8,36) have indicated that the efficacy of reversal therapies hinges upon the recovery of these cells rather than the generation of new -cells.”
Rui, J., Deng, S., Lebastchi, J., Clark, P. L., Usmani‐Brown, S., & Herold, K. C. (2016) · Diabetologia · doi:10.1007/s00125-016-3897-4 · Cited by 73
Self-citationβ cells persist in T1D pancreata without evidence of ongoing β-cell turnover or neogenesis
Lam, C. J., Jacobson, D. R., Rankin, M. M., Cox, A. R., & Kushner, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3806 · Cited by 68
Self-citationThe rise, fall, and resurgence of immunotherapy in type 1 diabetes
Nasr, M. B., D’Addio, F., Usuelli, V., Tezza, S., Abdi, R., & Fiorina, P. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.07.004 · Cited by 71
Harnessing the power of regulatory T‐cells to control autoimmune diabetes: overview and perspective
Yu, H., Paiva, R., & Flavell, R. A. (2017) · Immunology · doi:10.1111/imm.12867 · Cited by 70
Pugazhenthi, U., Velmurugan, K., Tran, A., Mahaffey, G., & Pugazhenthi, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1849-y · Cited by 61
“Other studies have used exendin-4 in combination with anti-inflammatory agents to demonstrate a more significant blocking of insulitis and diabetes onset in NOD mice [31–33].”
MethodMerani, S., Truong, W., Emamaullee, J. A., Toso, C., Knudsen, L. B., & Shapiro, A. M. J. (2008) · Endocrinology · doi:10.1210/en.2008-0501 · Cited by 61
“GLP-1 analogs have recently been discovered to have beneficial effects as adjunct therapy in type 1 diabetes mellitus models (11, 12), and in pancreatic islet transplant preclinical models (13–16).”
BackgroundAnti‐CD3 mAbs for treatment of type 1 diabetes
Kaufman, A. C., & Herold, K. C. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.933 · Cited by 60
Self-citationAston-Mourney, K., Hull, R. L., Zraika, S., Udayasankar, J., Subramanian, S. L., & Kahn, S. E. (2011) · Diabetologia · doi:10.1007/s00125-011-2143-3 · Cited by 56
“Beta cell proliferation has been shown to increase with exendin-4 treatment in many [19, 40], but not all, rodent studies [40, 41].”
Mathews, C. E., Xue, S., Posgai, A. L., Lightfoot, Y. L., Li, X., Lin, A., Wasserfall, C. H., Haller, M. J., Schatz, D., & Atkinson, M. A. (2015) · Diabetes · doi:10.2337/db15-0449 · Cited by 64
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U., Holst, J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
“However, so far most studies have failed to show any effect on ß-cell mass in animal models of type 1 diabetes [34]; an exception to this comes from a recent study where the combination of GLP-1 and gastrin increased ß-cell mass and showed evidence of a down regulation of the autoimmune response in the NOD-mouse [35].”
An update on the use of NOD mice to study autoimmune (Type 1) diabetes
Chaparro, R. J., & DiLorenzo, T. P. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.68 · Cited by 65
Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes
Villasenor, A., Wang, Z. V., Rivera, L. B., Ocal, O., Asterholm, I. W., Scherer, P. E., Brekken, R. A., Cleaver, O., & Wilkie, T. M. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.003210 · Cited by 55
Ghazi, T., Rink, L., Sherr, J. L., & Herold, K. C. (2014) · Diabetes Care · doi:10.2337/dc13-1169 · Cited by 54
“In addition to consideration of GLP-1 receptor agonists in the chronic metabolic management, these agents might be considered in combination with other agents, including immune modulators in the new-onset period (30).”
Self-citationKim, S.-J., Nian, C., & McIntosh, C. H. S. (2010) · Diabetes · doi:10.2337/db09-1618 · Cited by 54
Exendin‐4 Therapy in NOD Mice with New‐Onset Diabetes Increases Regulatory T Cell Frequency
Xue, S., Wasserfall, C. H., Parker, M., Brusko, T. M., McGrail, S., McGrail, K., Moore, M., Campbell‐Thompson, M., Schatz, D. A., Atkinson, M. A., et al. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.049 · Cited by 51
An update on preventive and regenerative therapies in diabetes mellitus
Reimann, M., Bonifacio, E. E., Solimena, M., Schwarz, P. E. H., Ludwig, B., Hanefeld, M., & Bornstein, S. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.009 · Cited by 64
“…peptide Animal studies, Phase II planned Bresson et al., 2006; http://www.dvdc.org.au Anti-CD3 MoAB + exenatide Animal studies, Phase II planned Sherry et al., 2007; http://diabetestrialnet.org Mycophenolate mofetil + anti-CD25 MoAB (Daclizumab) Open-label randomized trial, Phase II ongoing…”
BackgroundPang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
“Although GLP-1RAs showed no improvement in patients with type 1 diabetes (T1D), Sherry et al.93 demonstrated that exenatide could facilitate the reversal of T1D in NOD mice treated with the “therapeutic” anti-CD3 monoclonal antibody.”
BackgroundCho, J. M., Jang, H. W., Cheon, H., Jeong, Y. T., Kim, D., Lim, Y.-M., Choi, S., Yang, E.-K., Shin, C.-Y., Son, M. H., et al. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.10.012 · Cited by 52
“[31] Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, et al.”
Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Cabrera, S. M., Rigby, M. R., & Mirmira, R. G. (2012) · Current Molecular Medicine · doi:10.2174/156652412803833634 · Cited by 55
“In fact, GLP-1 stimulation delays diabetes development in NOD mice [103, 104] with the effect magnified when the GLP-1 receptor agonist is combined with the immunosuppressant therapies, such as anti-CD3 monoclonal antibody [105].”
BackgroundJelsing, J., Vrang, N., van Witteloostuijn, S. B., Mark, M., & Klein, T. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0479 · Cited by 52
“However, GLP1 is also known to play an immunomodulatory role in rodents, with the GLP1 receptor being expressed in immune cells from the spleen, thymus and lymph nodes of both non-diabetic and diabetic NOD mice (Sherry et al. 2007, Zhang et al. 2007, Hadjiyanni et al. 2008).”
Prevention of type 1 diabetes: the time has come
Sherr, J. L., Sosenko, J. M., Skyler, J. S., & Herold, K. C. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0832 · Cited by 51
Self-citationPozzilli, P., Bosi, E., Cirkel, D., Harris, J., Leech, N., Tinahones, F. J., Vantyghem, M.-C., Vlasakakis, G., Ziegler, A.-G., & Janmohamed, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa149 · Cited by 45
Glucose and Inflammation Control Islet Vascular Density and β-Cell Function in NOD Mice
Akirav, E. M., Baquero, M.-T., Opare-Addo, L. W., Akirav, M., Galvan, E., Kushner, J. A., Rimm, D. L., & Herold, K. C. (2011) · Diabetes · doi:10.2337/db10-0793 · Cited by 44
“Based on our previous studies (27), it is likely that the improved islet vasculature increases the insulin content of recovered degranulated b-cells, which accounts for the majority of b-cell mass recovery after treatment with anti-CD3 (2).”
Self-citationB cell depletion: a novel therapy for autoimmune diabetes?
Bour-Jordan, H., & Bluestone, J. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci34236 · Cited by 47
Self-citationGLP-1 agonists in type 1 diabetes
Pettus, J., Hirsch, I. B., & Edelman, S. V. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.006 · Cited by 48
“From the NOD mouse trials, combination with anti-CD3 was shown to augment reversal of disease as discussed above, but this success was not mirrored by a change in regulatory Tcells (Tregs) or autoreactive CD8+ cells [30].”
BackgroundAdjuvant Immunotherapy Increases β Cell Regenerative Factor Reg2 in the Pancreas of Diabetic Mice
Huszarik, K., Wright, B., Keller, C., Nikoopour, E., Krougly, O., Lee‐Chan, E., Qin, H.-Y., Cameron, M. J., Gürr, W., Hill, D. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001596 · Cited by 44
Rydén, A. K., Perdue, N., Pagni, P. P., Gibson, C. B., Ratliff, S. S., Kirk, R. K., Friesen, T. J., Haase, C., Coppieters, K. T., von Herrath, M. G., et al. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.006 · Cited by 49
Rapamycin Prevents and Breaks the Anti-CD3–Induced Tolerance in NOD Mice
Valle, A., Jofra, T., Stabilini, A., Atkinson, M. A., Roncarolo, M., & Battaglia, M. (2009) · Diabetes · doi:10.2337/db08-1432 · Cited by 46
Driver, J. P., Chen, Y., & Mathews, C. E. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.169 · Cited by 50
“Preclinical trials using anti-CD3 monoclonal antibodies in the NOD mouse had a 10% success when the therapy was initiated in mice with a blood sugar greater than 350 mg/dl, compared with reversal in 23 of 35 (66%) mice with circulating glucose levels less than 350 mg/dl [8].”
BackgroundMethodResultGrant, C. W., Duclos, S., Moran-Paul, C., Yahalom, B., Tirabassi, R. S., Arreaza-Rubín, G., Spain, L. M., & Guberski, D. L. (2012) · Europe PMC (PubMed Central) · Cited by 48
Faleo, G., Fotino, C., Bocca, N., Molano, R. D., Zahr, E., Molina, J., Villate, S., Umland, O., Skyler, J. S., Bayer, A. L., et al. (2012) · Diabetes · doi:10.2337/db11-0516 · Cited by 43
“Synergy has been reported after combining glucagon-like peptide-1 agonists with immunotherapy at the time of spontaneous diabetes onset in NOD mice (16,17,27).”
BackgroundHerold, K. C., Reynolds, J., Dziura, J., Baidal, D., Gaglia, J., Gitelman, S. E., Gottlieb, P. A., Marks, J., Philipson, L. H., Pop‐Busui, R., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14121 · Cited by 41
“Tropic effects of exendin-4 on β cells were shown in rodents after partial pancreatectomy, and synergy with immune therapy at the time of diabetes onset enhanced the insulin content of β cells.(8,9) Data from human studies have identified impaired function of residual β cells in patients with T1D, thus further support…”
BackgroundSelf-citationImmunotherapy for the Prevention and Treatment of Type 1 Diabetes
Bresson, D., & von Herrath, M. (2009) · Diabetes Care · doi:10.2337/dc09-0373 · Cited by 42
“As a result, clinical trials are under way to test their efficacy in a mono- or a combination therapy with anti-CD3 based on preclinical data (54).”
BackgroundVillalta, S. A., Lang, J., Kubeck, S., Kabre, B., Szot, G. L., Calderón, B., Wasserfall, C. H., Atkinson, M. A., Brekken, R. A., Pullen, N., et al. (2013) · Diabetes · doi:10.2337/db12-1619 · Cited by 39
“regeneration, previous studies have shown that the most likely effect of drugs on the islets is to reverse the metabolic stress caused by the immune response, leading to recovery of the insulin production by the remaining b-cells (49,50).”
ResultSelf-citationTime for Testing Incretin Therapies in Early Type 1 Diabetes?
Bosi, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2741 · Cited by 38
“to exenatide) showed a beneficial effect on -cell mass when administered together with anti-CD3 antibodies (3) oralonewithoutanyconcomitant immune intervention (4).”
BackgroundTherapies to Suppress β Cell Autoimmunity in Type 1 Diabetes
Kroger, C. J., Clark, M., Qi, K., & Tisch, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01891 · Cited by 43
Basta, G., Montanucci, P., & Calafiore, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13372 · Cited by 37
Valle, A., Barbagiovanni, G., Jofra, T., Stabilini, A., Pérol, L., Baeyens, A., Anand, S. K., Cagnard, N., Gagliani, N., Piaggio, E., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401551 · Cited by 32
Riedel, M. J., Gaddy, D. F., Asadi, A., Robbins, P. D., & Kieffer, T. J. (2009) · Gene Therapy · doi:10.1038/gt.2009.143 · Cited by 33
Kim, D.-H., Lee, J.-C., Lee, M., Kim, K.-W., & Lee, M.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2723-x · Cited by 32
Phillips, B. E., Trucco, M., & Giannoukakis, N. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/432016 · Cited by 36
“Examples include combining the antiCD3 antibody with beta-cell-protective and functionenhancing GLP-1 agonists [165, 166], IL-1-neutralising antibodies with the anti-CD3 antibody (http://www.”
BackgroundNti, B. K., Markman, J. L., Bertera, S., Styche, A. J., Lakomy, R. J., Subbotin, V. M., Trucco, M., & Zorina, T. D. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.36 · Cited by 30
Tian, J., Dang, H. N., O’Laco, K. A., Song, M., Tiu, B.-C., Gilles, S., Zakarian, C., & Kaufman, D. L. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900019 · Cited by 31
“These functional islets had a surrounding periinsulitis, a feature of functional islets that has been observed in past studies of anti-CD3– treated diabetic mice (53, 64, 65).”
Son, D. O., Liu, W., Li, X., Prud’homme, G. J., & Wang, Q. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12881 · Cited by 31
“The biologically active forms of GLP-1 are GLP-1(7-36) amide and GLP-1(7-37).”
BackgroundRole of immune system modulation in prevention of type 1 diabetes mellitus
Hassan, G. A., Sliem, H. A., Ellethy, A. T., & Salama, M.-S. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.102989 · Cited by 31
“[38] In addition, systemic antiinfl ammatory agents such as IL-1 receptor antagonists[39] and agents that stimulate β-cell proliferation[40] are being studied as potential components of a multidrug prevention of β-cell destruction.”
BackgroundTreatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development
Vudattu, N. K., & Herold, K. C. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.881797 · Cited by 28
“Addition of a b-celldirected agent, the glucagon-like peptide-1 receptor agonist exendin-4 improved the remission of diabetes in NOD mice and function of residual islets in mice [56].”
BackgroundSelf-citationRegulatory mechanisms of immune tolerance in type 1 diabetes and their failures
Kuhn, C., Besançon, A., Lemoine, S., You, S., Marquet, C., Candon, S., & Chatenoud, L. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.05.002 · Cited by 33
Dejgaard, T. F., Frandsen, C. S., Kielgast, U., Størling, J., Overgaard, A. J., Svane, M. S., Olsen, M. H., Thorsteinsson, B., Andersen, H. U., Krarup, T., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15889 · Cited by 29
Ding, L., Gysemans, C. A., Stangé, G. M., Heremans, Y., Yuchi, Y., Takiishi, T., Korf, H., Chintinne, M., Carr, R. D., Heimberg, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107935 · Cited by 28
“observations [7], the majority of pancreatic islets of untreated”
BackgroundVarin, E. M., Wojtusciszyn, A., Broca, C., Muller, D. S., Ravier, M. A., Ceppo, F., Renard, É., Tanti, J., & Dalle, S. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.399 · Cited by 32
Hypochlorous acid reversibly inhibits caspase-3: a potential regulator of apoptosis
Jeelani, R., Chatzicharalampous, C., Kohan‐Ghadr, H., Bai, D., Morris, R. T., Sliskovic, I., Awonuga, A. O., & Abu‐Soud, H. M. (2020) · Free Radical Research · doi:10.1080/10715762.2019.1694675 · Cited by 27
“The apoptosis signal was detected using confocal microscopy, with the Zeiss LSM 780 META NLO microscope, using DAPI [48] and the CellEvent fluorescent reagent (green) with emission wavelength of 358 and 461 nm and 502 and 530 nm respectively.”
MethodInfluentialChapter 2 CD3 Antibodies as Unique Tools to Restore Self-Tolerance in Established Autoimmunity
You, S., Candon, S., Kuhn, C., Bach, J., & Chatenoud, L. (2008) · Advances in immunology · doi:10.1016/s0065-2776(08)00802-x · Cited by 28
“Indeed, the combination of exendin-4 and CD3 monoclonal antibody therapy led to a more effective reversal of spontaneous diabetes in NOD mice by enhancing the insulin content of pancreatic b-cells as compared with treatment with either agent alone (Sherry et al., 2007).”
BackgroundJörns, A., Ertekin, Ü. G., Arndt, T., Terbish, T., Wedekind, D., & Lenzen, S. (2015) · Diabetes · doi:10.2337/db14-1866 · Cited by 28
“Combination therapies, at variance from monotherapies, have shown promising results in T1D 68 (25-29) and other autoimmune diseases (11,14,15).”
BackgroundChemical Immunosuppression in Islet Transplantation — Friend or Foe?
Chatenoud, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmcibr0708067 · Cited by 30
Immunotherapy of type 1 diabetes — How to rationally prioritize combination therapies in T1D
Boettler, T., & von Herrath, M. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.07.008 · Cited by 26
Jörns, A., Akin, M., Arndt, T., Terbish, T., zu Vilsendorf, A. M., Wedekind, D., Hedrich, H.-J., & Lenzen, S. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1137-2 · Cited by 30
Wright, L. A.-C., & Hirsch, I. B. (2019) · Diabetic Medicine · doi:10.1111/dme.13941 · Cited by 30
The potential of incretin-based therapies in type 1 diabetes
Suen, C. S., & Burn, P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.017 · Cited by 30
β ‐Cell differentiation and regeneration in type 1 diabetes
Ding, L., Gysemans, C. A., & Mathieu, C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12164 · Cited by 31
Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents
Grant, C. W., Moran-Paul, C., Duclos, S., Guberski, D. L., Arreaza-Rubín, G., & Spain, L. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072989 · Cited by 26
Oligofructose as an adjunct in treatment of diabetes in NOD mice
Chan, C., Hyslop, C. M., Shrivastava, V., Ochoa, A., Reimer, R. A., & Huang, C. (2016) · Scientific Reports · doi:10.1038/srep37627 · Cited by 26
Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes
Mignogna, C., Maddaloni, E., D’Onofrio, L., & Buzzetti, R. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2022119 · Cited by 24
Wållberg, M., Recino, A., Phillips, J. M., Howie, D., Vienne, M., Paluch, C., Azuma, M., Wong, F. S., Waldmann, H., & Cooke, A. (2017) · Immunology · doi:10.1111/imm.12729 · Cited by 28
Stanisavljević, I., Pavlovic, S. M., Marković, B. S., Jurišević, M., Krajnović, T., Mijatović, S., Spasojević, M., Mitrović, S., Corovic, I. F., & Jovanović, I. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117668 · Cited by 35
Anderson, R. L., DiMeglio, L. A., Mander, A., Dayan, C. M., Linsley, P. S., Herold, K. C., Marinac, M., & Ahmed, S. T. (2022) · Diabetes Care · doi:10.2337/dc22-0308 · Cited by 25
Self-citationCharacterization of residual β cell function in long‐standing type 1 diabetes
Sherr, J. L., Ghazi, T., Wurtz, A., Rink, L., & Herold, K. C. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2478 · Cited by 27
Self-citationBesançon, A., Goncalves, T., Valette, F., Dahllöf, M. S., Mandrup-Poulsen, T. R., Chatenoud, L., & You, S. (2017) · Diabetologia · doi:10.1007/s00125-017-4459-0 · Cited by 25
Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus
Guglielmi, C., Williams, S. R., Toro, R. D., & Pozzilli, P. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1180363 · Cited by 22
Prevention of type 1 diabetes: today and tomorrow
Cernea, S., Dobreanu, M., & Raz, I. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1138 · Cited by 24
Prolactin as an Adjunct for Type 1 Diabetes Immunotherapy
Hyslop, C. M., Tsai, S. J., Shrivastava, V., Santamaría, P., & Huang, C. (2015) · Endocrinology · doi:10.1210/en.2015-1549 · Cited by 22
Self-citation
Metadata
- Authors
- Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C.
- Affiliations
- Columbia University Irving Medical Center (US)
- Yale University (US)
- Children's Hospital of Philadelphia (US)
- University of California, San Francisco (US)
- University of Calgary (CA)
- Julia McFarlane Diabetes Research Centre and Department of Microbiology and Infectious Diseases (S.T., P.S.), University of Calgary, Calgary, Alberta, Canada T2N 1N4
- Corresponding author
- Herold, Kevan C.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-11-01
- Volume
- 148
- Issue
- 11
- Pages
- 5136-5144
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1983796537
- Cited by
- 169
- References
- 34
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 19 · 2012: 16
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pediatric Endocrine Society
- Alberta Heritage Foundation for Medical Research
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI98-010)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 57846, DK068678, K08DK064101, R01DK068678, P30DK063608, R01DK057846)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- exendin-4, GLP-1 receptor agonists, type 1 diabetes, diabetes remission, anti-CD3 monoclonal antibody, beta-cell recovery, NOD mice, insulin secretion, GLUT2, immunomodulation, combination therapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Antibodies, Monoclonal, Cells, Cultured, Combined Modality Therapy, Diabetes Mellitus, Type 1, Female, Immunotherapy, Peptides, Remission Induction, Venoms, Mice, SCID, Mice, Inbred NOD, CD3 Complex, Receptors, Glucagon, Insulin-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.